Can we stop aspirin after just one month of DAPT following PCI without compromising ischaemic safety?
An analysis of 11 randomized trials involving 37,443 patients found that P2Y12-inhibitor monotherapy substantially reduced bleeding, with broadly comparable ischaemic outcomes following one- versus three-month aspirin withdrawal. However, an early ischaemic signal with near-immediate withdrawal highlights the importance of timing.
Does the future of post-PCI antiplatelet therapy lie in earlier aspirin withdrawal?
Read the study and share your perspective!
#Cardiology #CardioTwitter #PCI #AntiplateletTherapy #InterventionalCardiology
pubmed.ncbi.nlm.nih.gov/42832633
@drhbulluck
An analysis of 11 randomized trials involving 37,443 patients found that P2Y12-inhibitor monotherapy substantially reduced bleeding, with broadly comparable ischaemic outcomes following one- versus three-month aspirin withdrawal. However, an early ischaemic signal with near-immediate withdrawal highlights the importance of timing.
Does the future of post-PCI antiplatelet therapy lie in earlier aspirin withdrawal?
Read the study and share your perspective!
#Cardiology #CardioTwitter #PCI #AntiplateletTherapy #InterventionalCardiology
pubmed.ncbi.nlm.nih.gov/42832633
@drhbulluck